OC
PDSB icon

Oppenheimer & Co’s PDS Biotechnology PDSB Stock Holding History

Oppenheimer & Co’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,250
Closed -$81K – 1441
2022
Q2 		$81K Sell
22,250
-2,750
-11% -$13.1K ﹤0.01% 1347
2022
Q1 		$155K Buy
25,000
+11,000
+79% +$68.3K ﹤0.01% 1388
2021
Q4 		$114K Buy
14,000
+1,350
+11% +$14.5K ﹤0.01% 1439
2021
Q3 		$188K Buy
12,650
+100
+0.8% +$1.25K ﹤0.01% 1407
2021
Q2 		$158K Buy
+12,550
New +$98K ﹤0.01% 1447

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Oppenheimer & Co's PDSB Position: Q3 2022 in Review

Oppenheimer & Co sold out of PDS Biotechnology (PDSB) in Q3 2022, closing a stake of 22,250 shares — an estimated $81K sold.

Oppenheimer & Co first reported a position in PDSB in Q2 2021 and held it in 5 quarters. The position peaked at $188K in Q3 2021. 47 funds tracked by Wall St. Rank hold PDSB as of Q3 2022.

  • Oppenheimer & Co reported no remaining PDS Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 22,250 PDS Biotechnology shares in Q3 2022, an estimated $81K.
  • Oppenheimer & Co first reported a position in PDS Biotechnology in Q2 2021 and held it in 5 quarters.
  • Oppenheimer & Co's PDS Biotechnology position peaked at $188K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2022.

Based on Oppenheimer & Co's 13F filing for Q3 2022, filed 14 Nov 2022.